---
title: "Liver Health: ASAT, ALAT and Oral Steroids"
description: "17aa orals and the liver: ASAT/ALAT markers, TUDCA/NAC support, why duration matters, harm reduction tips."
lang: en
dateModified: 2026-05-23
canonical: https://anaprotokol.com/en/guides/liver-health-oral-steroids
---

# Liver Health: ASAT, ALAT and Oral Steroids

The **17-alpha-alkylated oral steroids** ([Dianabol](/en/molecule/dianabol), [Anadrol](/en/molecule/anadrol), [Winstrol](/en/molecule/winstrol), [Anavar](/en/molecule/anavar)) tax the liver in a meaningful way. The hepatotoxicity is documented, dose-dependent and duration-dependent. It is measured on the liver panel — not on feel — and it dictates simple rules: limit the duration, monitor, supplement with intent.

This guide explains the 17-alpha-alkylation mechanism, details the liver markers worth watching (AST, ALT, GGT, bilirubin), gives the warning thresholds, and covers the best practices (TUDCA, NAC, duration). It belongs to the [blood work on cycle](/en/guides/blood-work-on-cycle) cluster.

## The mechanism: why orals are hepatotoxic

For a steroid to survive first-pass hepatic metabolism (the liver process that breaks down ingested substances before they reach systemic circulation), it has to be **17-alpha-alkylated** (17α-aa) — a methyl group added at position 17 of the steroid nucleus. This chemical modification makes the oral route possible… at the cost of a heavy load on the liver, which has to metabolize a modified molecule resistant to its own degradation pathways.

Clinical consequences observed: rising transaminases (AST, ALT), bile function impairment (cholestasis), possible bilirubin rise, and more rarely (but documented on long high-dose use) hepatic peliosis, adenomas and serious hepatic damage [2]. The risk is clearly dose- and duration-dependent [1].

### Oral compounds and their hepatic footprint

- **Anadrol (oxymetholone).** Often cited as one of the most toxic orals for the liver. See the [Anadrol](/en/molecule/anadrol) page.
- **Dianabol (methandrostenolone).** Significant hepatotoxicity at standard dose and duration.
- **Winstrol (stanozolol).** Hepatotoxic, plus the most pronounced lipid impact.
- **Anavar (oxandrolone).** Considered the best-tolerated oral on the liver at standard doses, but not inert either.
- **Turinabol (chlorodehydromethyltestosterone).** Moderate hepatotoxicity at standard dose, duration to keep limited.

> Non-17α-alkylated injectables (testosterone esters, nandrolone, boldenone, masteron, primobolan, trenbolone) do not impose the same liver load. That is the structural argument in favor of 'all-injectable' cycles for users wanting to preserve their liver long-term. See the [oral vs injectable steroids](/en/guides/oral-vs-injectable-steroids) guide.

## Liver markers and their thresholds

| Marker | Adult reference | Reading under orals |
| --- | --- | --- |
| AST (ASAT) | < 40 IU/L | Also present in muscle; an isolated rise can come from training |
| ALT (ALAT) | < 40 IU/L | More specific to the liver than AST |
| GGT | < 60 IU/L (male) | Sensitive marker of hepatic stress and cholestasis |
| Alkaline phosphatase (ALP) | 40–130 IU/L | Elevation = cholestatic signal |
| Total bilirubin | < 1.2 mg/dL | Elevation = cholestatic signal |
| Albumin | 35–50 g/L | Stable unless severe damage |

### AST vs ALT: the training trap

AST is in the liver but also in muscle. After an intense training session (heavy lifting, hard hypertrophy work), AST can be elevated without any liver issue. That is why, to evaluate hepatic stress, you look mainly at ALT (more liver-specific) and GGT alongside [3]. A high AST with normal ALT and GGT points to a muscular origin.

> To limit the muscle bias, the rule is to **avoid training in the 48 to 72 hours before the draw**. That brings AST back to a more representative level and avoids false hepatic alerts.

### Warning thresholds

- **1 to 3× the reference range.** Monitor; common under orals; recheck at 2–3 weeks.
- **> 3× the reference range.** Alert: consider stopping the oral and re-consulting [5].
- **> 5× the reference range.** Stop the oral and seek medical attention promptly; recheck within 1–2 weeks.
- **Elevated bilirubin or ALP + jaundice, dark urine.** Immediate stop of the oral and prompt consult — signs of cholestasis.

## Best practices to limit hepatic load

### 1. Limit duration

The commonly accepted rule: **4 to 6 weeks maximum on an oral**, exceptionally 8 weeks for the best-tolerated compounds (Anavar) in a well-controlled cycle. Past that, the hepatic risk/benefit ratio deteriorates clearly, without proportional muscle gain [2].

### 2. Do not stack orals

Stacking two 17α-alkylated orals (for example Dianabol + Winstrol, or Anavar + Winstrol) doubles the liver load with no major muscle benefit. This is a practice to avoid, especially for beginners and intermediates [4].

### 3. Supplementation: TUDCA and NAC

- **TUDCA (tauroursodeoxycholic acid).** The most systematically cited supplement. Helps thin bile and protect hepatocytes from the cholestatic stress of 17α-aa compounds. Usual dose: 250 to 500 mg/day for the duration of the oral.
- **NAC (N-acetylcysteine).** Precursor of glutathione, the liver's major antioxidant. Usual dose: 600 to 1200 mg/day.
- **Milk thistle (silymarin).** Documented hepatoprotective effect but often judged inferior to TUDCA for the specific 17α-aa context. Can be added; not a substitute.

> No supplement makes an oral harmless to the liver. TUDCA and NAC buffer the load, they do not erase it. Supplementation justifies the cautious maximum duration, it does not extend it.

### 4. Alcohol and co-medications

- **Alcohol: avoid during the oral phase.** Alcohol stacks with the hepatic load of orals and meaningfully raises risk.
- Limit acetaminophen (Tylenol) during the oral phase — it is also hepatotoxic at cumulative dose.
- Flag hepatotoxic co-medications (long-term antibiotics, prolonged NSAIDs, etc.) to your doctor if you are being followed.

## Liver monitoring schedule

- **Baseline before cycle:** AST, ALT, GGT, ALP, total bilirubin.
- **During the oral phase:** check toward the end of week 4 if the oral runs 6 to 8 weeks.
- **End of cycle:** 1 to 2 weeks after fully stopping the oral.
- **Post-PCT:** included in the global recovery panel.

For the global schedule (CBC, hormonal, lipid, hepatic), see [blood test schedule for a cycle](/en/guides/blood-test-schedule-cycle). Lab PDFs can be imported into AnaProtoKol's [blood work feature](/register) (8 panels, 59 markers) to track transaminases over time with the baseline as reference.

## FAQ

### My AST/ALT are at 2× the range: should I stop?

A moderate rise (1 to 3× range) is common under orals. The first reflex is to check that the draw did not follow an intense training session (AST also rises from muscle). Redrawing 48 to 72 hours away from training often clarifies things. If the elevation is confirmed at 2× range, the usual call is to finish the current oral window (without extending it), keep TUDCA and NAC, and recheck after stopping. Past 3× range confirmed, stopping the oral becomes the reasonable decision.

### Does TUDCA alone protect the liver?

No, TUDCA is not a shield. It buffers the cholestatic load of 17α-alkylated compounds, but the hepatotoxicity stays present — simply reduced. Protection comes first from duration limits (4 to 6 weeks), no oral stacking, alcohol cut during the oral phase, and only then from the supplement. Resting your protection on TUDCA alone is a misread of its role.

### Since Anavar is 'easy on the liver', can I run it past 8 weeks?

Anavar is probably the best-tolerated 17α-alkylated compound, but it is not inert. Past 8 weeks, the hepatic risk/benefit ratio deteriorates: cumulative transaminase rise possible, persistent lipid impact, and marginal extra muscle benefit. If the need is for a longer oral window, it is safer to split (for example 6 weeks, break, 4 to 6 weeks) than to run straight through without interruption.